Notice of Proposed Sale · 144
GeneDx Holdings Corp.
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- GeneDx Holdings Corp.
- Issuer CIK
- 0001818331
- SEC file number
- 001-39482
- Phone
- 888-729-1206
- Person for whose account securities are to be sold
- Kevin Feeley
- Relationships to issuer
- Officer
- Street
- 333 Ludlow St, North Tower
- Street (continued)
- 6th Floor
- City
- Stamford
- State / country code
- CT
- Postal code
- 06902
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Class A Common Stock | 5,410 | 458,500 | 29,822,541 | 09/01/2026 | NASDAQ | Morgan Stanley Smith Barney |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney
- Street
- 2000 Westchester Avenue
- City
- Purchase
- State / country code
- NY
- Postal code
- 10577
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | 09/01/2022 | Acquired as compensation - Restricted Stock Units | Issuer | 372 | N | 09/01/2022 | Compensation |
| Class A Common Stock | 12/09/2022 | Acquired as compensation - Restricted Stock Units | Issuer | 1,284 | N | 12/09/2022 | Compensation |
| Class A Common Stock | 04/26/2023 | Acquired as compensation - Restricted Stock Units | Issuer | 3,754 | N | 04/26/2023 | Compensation |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Kevin Feeley | Class A Common Stock | 06/01/2026 | 369 | 19,092 |
| Kevin Feeley | Class A Common Stock | 06/09/2026 | 1,266 | 68,073 |
| Kevin Feeley | Class A Common Stock | 06/16/2026 | 3,729 | 226,597 |
Seller — prior-sale row 1, entry 1
- Name
- Kevin Feeley
- Street
- 333 Ludlow St, North Tower
- Street (continued)
- 6th Floor
- City
- Stamford
- State / country code
- CT
- Postal code
- 06902
Seller — prior-sale row 2, entry 1
- Name
- Kevin Feeley
- Street
- 333 Ludlow St, North Tower
- Street (continued)
- 6th Floor
- City
- Stamford
- State / country code
- CT
- Postal code
- 06902
Seller — prior-sale row 3, entry 1
- Name
- Kevin Feeley
- Street
- 333 Ludlow St, North Tower
- Street (continued)
- 6th Floor
- City
- Stamford
- State / country code
- CT
- Postal code
- 06902
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
Represents approximately 5,410 shares to be sold on behalf of the Reporting Person, including 1) 372 shares to be sold in connection with anticipated vesting of RSUs on September 1, 2026; 2) approximately 1,284 shares to be sold in connection with anticipated vesting of RSUs on September 9, 2026; and 3) approximately 3,754 shares to be sold in connection with anticipated vesting of RSUs on September 16, 2026. Shares sold in the past 3 months by the Reporting Person include 5,364 shares sold to cover tax withholding obligations in connection with vesting and settlement of RSUs.
Notice signature
- Notice date
- 09/01/2026
- Signed
- /s/ Kevin Feeley
Company context
GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity ™ - the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx ™ and GenomeDx ® tests - ranked #1 by expert geneticists and granted FDA Breakthrough Device designation - enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,100 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.
Current securities
Historical securities (8)
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureNov 18, 2026
- SCHEDULE 13G/A - filed by ARK Investment Management LLC regarding GeneDx Holdings Corp.Nov 13, 2026
- 10-Q filingNov 9, 2026
- Results of Operations and Financial ConditionNov 9, 2026
- SCHEDULE 13G - filed by WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC regarding GeneDx Holdings Corp.Nov 6, 2026